论文部分内容阅读
目的 探讨血小板衍化内皮细胞生长因子 (PD ECGF)依赖的化疗药卡培他滨(Capecitabine,CAP)对肝癌切除术后复发转移的作用。 方法 用免疫组化方法检测 18例LCI D2 0裸鼠人肝癌高转移模型中肝癌和肺转移灶中的PD ECGF表达。用 2 4只LCI D2 0裸鼠 ,于肝癌组织原位种植后第 10天行根治性肝癌切除术 ,术后第 3天分别采用CAP和 5 氟尿嘧啶治疗。停药后第 3天处死裸鼠 ,观察肝内有无肿瘤复发。若有则测量复发灶的长短径。检测裸鼠肝功能和血浆甲胎蛋白(AFP)水平 ,并用HE染色检测肺转移。 结果 18例肝癌和肺转移灶组织中均表达PD ECGF。CAP治疗后 ,肝内复发癌灶体积 [(16 8± 2 0 6 )mm3 ]以及AFP水平 [(10 7± 90 )ng/ml]明显小于对照组肝癌体积 [(316 2± 6 90 )mm3 ]以及AFP水平 [(15 19± 80 7)ng/ml],P <0 0 5 ;裸鼠肝内复发率和肺转移率也明显下降 ,P <0 0 5。而 5 氟尿嘧啶治疗组与对照组比较以上指标差异均无显著性意义 (P >0 0 5 )。 结论 CAP治疗能抑制高转移性人肝癌切除术后的复发转移。
Objective To investigate the effect of capecitabine (CAP), a platelet-derived endothelial cell growth factor (PD ECGF)-dependent chemotherapy drug, on recurrence and metastasis after hepatectomy. Methods Immunohistochemistry was used to detect PD ECGF expression in liver cancer and lung metastases in 18 cases of human hepatoma high metastasis model of LCI D2 0 nude mice. Twenty-four nude mice bearing LCI D2 0 were used to perform radical hepatectomy on the 10th day after orthotopic implantation of HCC tissue. CAP and 5-fluorouracil were used on the third postoperative day. The nude mice were sacrificed on the third day after discontinuation of the drug to observe whether there was recurrence of the tumor in the liver. If so, measure the length and length of the recurrent foci. The liver function and plasma alpha-fetoprotein (AFP) levels in nude mice were measured and HE staining was used to detect lung metastases. Results PD ECGF was expressed in 18 cases of liver cancer and lung metastases. After CAP treatment, the intrahepatic recurrent foci volume [(16 8 ± 2 0 6) mm3] and AFP level [(10 7 ± 90) ng/ml] were significantly smaller than those of the control group [(316 2 ± 6 90) mm 3 And AFP levels [(15 19 ± 80 7) ng/ml], P <0 05; The intrahepatic recurrence rate and lung metastasis rate of nude mice also decreased significantly, P <0 05. There was no significant difference in the above indicators between the 5-fluorouracil treatment group and the control group (P > 0 05). Conclusion CAP treatment can inhibit the recurrence and metastasis of highly metastatic human hepatic carcinoma after resection.